BRAF and metastatic melanoma: B-Raf(V600E) inhibitors, such as Dabrafenib, are an important anticancer drug class for metastatic melanoma therapy, that seem to inhibit the RIPK3 enzymatic activity in vitro, through their ATP-competitive binding to the enzyme [141].